What is rapid initiation?

Breaking down what you should know if you’ve just been diagnosed with HIV.

Many healthcare providers are prescribing treatment immediately after an HIV diagnosis rather than waiting for results of initial testing. This is sometimes called rapid initiation. According to the CDC, beginning treatment as soon as possible is important for your immediate health and may reduce the risk of passing HIV to others.

Why rapidly treat HIV?

Before rapid initiation was practiced, patients would go through rounds of testing and doctor’s visits before getting on medication. This can delay the benefits of treatment, allowing the viral load, or the amount of HIV in the body, to go up.

Recent research has shown that starting treatment quickly after diagnosis may help patients reach an undetectable viral load (<50 copies/mL) sooner than if they delayed treatment. This may help decrease the chances of transmitting HIV.

Reaching undetectable doesn't mean you're 100% unable to transmit the virus. So, when you're talking to your provider about why rapid initiation is the new standard in treatment, also ask about other ways of preventing the spread of HIV and other STDs.

Learn more about rapid initiation and SYMTUZA®.

WHAT IS SYMTUZA®?
SYMTUZA® is a prescription medicine that is used without other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults and in children who weigh at least 88 pounds (40 kg) who:
• have not received anti-HIV-1 medicines in the past, or
• when their healthcare provider determines that they meet certain requirements.
HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). It is not known if SYMTUZA® is safe and effective in children weighing less than 88 pounds (40 kg).

IMPORTANT SAFETY INFORMATION
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT SYMTUZA®?
SYMTUZA® can cause serious side effects including:
• Worsening of hepatitis B virus infection. Your healthcare provider will test you for hepatitis B virus (HBV) before starting treatment with SYMTUZA®. If you have HBV infection and take SYMTUZA®, your HBV may get worse (flare-up) if you stop taking SYMTUZA®.
• Do not stop taking SYMTUZA® without first talking to your healthcare provider.
• Do not run out of SYMTUZA®. Refill your prescription or talk to your healthcare provider before your SYMTUZA® is all gone.
• If you stop taking SYMTUZA®, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your HBV infection or give you a medicine to treat your HBV infection. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking SYMTUZA®.
• Change in liver enzymes. People with a history of hepatitis B or C virus infection or who have certain liver enzyme changes may have an increased risk of developing new or worsening liver problems during treatment with SYMTUZA®. Liver problems can also happen during treatment with SYMTUZA® in people without a history of liver disease. Your healthcare provider may need to do tests to check your liver enzymes before and during treatment with SYMTUZA®.

Please read additional Important Safety Information on the next page and full Product Information, including Boxed WARNING for SYMTUZA®, and discuss any questions you have with your doctor.
The DIAMOND Study

100% of patients on SYMTUZA® were able to decrease their viral load to a low level (<200 copies/mL) after 48 weeks.*

A few patients (13 out of 109) left the study. Of the remaining 96 patients, 96% reached an undetectable viral load (viral load <50 copies/mL).*

Fewer than 1% stopped taking SYMTUZA® due to side effects. The most common side effects occurring in at least 2% of patients taking SYMTUZA® were diarrhea, nausea, rash, vomiting, and fatigue.

These are not the only side effects of SYMTUZA®. Before starting SYMTUZA®, you should get tested for hepatitis B virus and kidney function.

*This excludes patients with missing data.

SYMTUZA® was studied in 109 newly diagnosed HIV patients (within 14 days) who started treatment before receiving lab results.

All patients received SYMTUZA®, and the study measured the number of patients who were undetectable (viral load <50 copies/mL) after 48 weeks of treatment.

The DIAMOND study was completed after FDA approval of SYMTUZA®. The safety and effectiveness of SYMTUZA® in patients who had never been treated for HIV was determined in the AMBER study.

When all 109 patients were accounted for, whether they completed the study or not, 84% reached undetectable and 8% of patients did not reach undetectable (viral load <50 copies/mL) after 48 weeks of treatment.

IMPORTANT SAFETY INFORMATION (CONTINUED)

• Severe liver problems. In rare cases, severe liver problems can happen that can lead to death. Tell your healthcare provider right away if you get these symptoms:
  • Skin or the white part of your eyes turn yellow
  • Dark “tea-colored” urine
  • Light-colored stools
  • Loss of appetite for several days or longer
  • Nausea
  • Vomiting
  • Stomach area pain

SYMTUZA® may cause severe or life-threatening skin reactions or rashes which may sometimes require treatment in a hospital. Call your healthcare provider right away if you develop a rash.

Stop taking SYMTUZA® and call your healthcare provider right away if you develop any skin changes with symptoms below:
  • Fever
  • Tiredness
  • Muscle or joint pain
  • Blisters or skin lesions
  • Mouth sores or ulcers
  • Red or inflamed eyes, like “pink eye” (conjunctivitis)

Please read additional Important Safety Information on the next page and full Product Information, including Boxed WARNING for SYMTUZA®, and discuss any questions you have with your doctor.
IMPORTANT SAFETY INFORMATION (CONTINUED)

Who should not take SYMTUZA®?

• Do not take SYMTUZA® with any of the following medicines: alfuzosin, carbamazepine, cisapride, colchicine (if you have liver or kidney problems), dronedarone, elbasvir and grazoprevir, ergot-containing medicines (such as: dihydroergotamine, ergotamine tartrate, methylergonovine), ivabradine, lomitapide, lovastatin or a product that contains lovastatin, lurasidone, midazolam (when taken by mouth), naloxegol, phenobarbital, phenytoin, pimozide, ranolazine, rifampin, St. John’s wort (Hypericum perforatum) or a product that contains St. John’s wort, sildenafil when used for pulmonary arterial hypertension (PAH), simvastatin or a product that contains simvastatin, or triazolam.

• Serious problems can happen if you take any of these medicines with SYMTUZA®.

Before taking SYMTUZA®, tell your healthcare provider about all of your medical conditions, including if you:

• have liver problems (including hepatitis B or hepatitis C), have kidney problems, are allergic to sulfa (sulfonamide), have diabetes, have hemophilia, or have any other medical condition.
• are pregnant (if you become pregnant while taking SYMTUZA®), or plan to become pregnant. It is unknown if SYMTUZA® will harm your unborn baby.
• SYMTUZA® should not be used during pregnancy.
• are breastfeeding or plan to breastfeed. Do not breastfeed if you take SYMTUZA®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines interact with SYMTUZA®. Keep a list of your medicines to show your healthcare provider and pharmacist. Do not start taking a new medicine without telling your healthcare provider.

HOW SHOULD I TAKE SYMTUZA®?

• Take SYMTUZA® 1 time a day with food.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF SYMTUZA®?

SYMTUZA® may cause serious side effects including:

• Immune system changes can happen in people who start HIV medications.

Please read above Important Safety Information and full Product Information including Boxed WARNING for SYMTUZA®, and discuss any questions you have with your doctor.

© Janssen Therapeutics, Division of Janssen Products, LP 2020  10/20  cp-62077v4

You may report side effects to the FDA at 1-800-FDA-1088 or to Janssen Products, LP at 1-800-JANSSEN (1-800-526-7736).